Your browser is no longer supported. Please, upgrade your browser.
Relay Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.69 Insider Own0.70% Shs Outstand89.91M Perf Week0.91%
Market Cap3.02B Forward P/E- EPS next Y-2.29 Insider Trans-89.67% Shs Float86.23M Perf Month-13.51%
Income-230.20M PEG- EPS next Q-0.48 Inst Own95.90% Short Float9.49% Perf Quarter-40.20%
Sales82.70M P/S36.48 EPS this Y-195.40% Inst Trans3.80% Short Ratio11.84 Perf Half Y-20.48%
Book/sh8.49 P/B3.80 EPS next Y-15.00% ROA-40.60% Target Price54.60 Perf Year-
Cash/sh7.25 P/C4.45 EPS next 5Y- ROE-87.80% 52W Range30.72 - 64.37 Perf YTD-22.38%
Dividend- P/FCF- EPS past 5Y- ROI-7.30% 52W High-49.88% Beta-
Dividend %- Quick Ratio56.50 Sales past 5Y- Gross Margin- 52W Low5.03% ATR2.43
Employees159 Current Ratio56.50 Sales Q/Q- Oper. Margin- RSI (14)38.80 Volatility7.59% 7.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-82.90% Profit Margin- Rel Volume0.30 Prev Close32.63
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume691.21K Price32.26
Recom2.00 SMA20-7.34% SMA50-17.31% SMA200-23.10% Volume214,572 Change-1.13%
Dec-15-20Reiterated H.C. Wainwright Buy $54 → $57
Dec-08-20Initiated JMP Securities Mkt Outperform $66
Nov-05-20Initiated H.C. Wainwright Buy $54
Aug-10-20Initiated JP Morgan Neutral $36
Aug-10-20Initiated Guggenheim Buy $48
Aug-10-20Initiated Goldman Buy $64
Aug-10-20Initiated Cowen Outperform
Apr-16-21 11:31AM  
Apr-14-21 05:57AM  
Mar-25-21 04:05PM  
Mar-10-21 04:30PM  
Feb-04-21 04:05PM  
Jan-14-21 04:26AM  
Jan-06-21 05:00PM  
Dec-16-20 10:36PM  
Dec-14-20 06:00AM  
Nov-12-20 04:05PM  
Oct-16-20 10:53AM  
Sep-03-20 04:05PM  
Aug-27-20 06:50AM  
Aug-16-20 08:59AM  
Aug-11-20 06:40AM  
Aug-06-20 06:07PM  
Jul-20-20 04:05PM  
Jul-17-20 04:17PM  
Jul-16-20 04:28PM  
Jul-15-20 08:51PM  
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bergstrom Donald ASee RemarksApr 16Sale32.3656,3241,822,64577,241Apr 20 07:08 PM
Adams BrianGeneral CounselJan 28Option Exercise4.125,00020,60015,000Jan 29 09:00 PM
Adams BrianGeneral CounselJan 28Sale55.055,000275,25010,000Jan 29 09:00 PM
Third Rock Ventures III, L.P.10% OwnerJan 14Sale41.001,965,29480,577,0540Jan 14 08:44 PM
Third Rock Ventures III, L.P.10% OwnerJan 13Sale40.13845,90333,942,6521,965,294Jan 14 08:44 PM
Third Rock Ventures III, L.P.10% OwnerJan 13Sale40.131,311,19752,613,0067,739,918Jan 14 08:44 PM
Third Rock Ventures III, L.P.10% OwnerJan 12Sale40.001,500,00060,000,0009,051,115Jan 14 08:44 PM